Fukutin (FKTN)

Fukutin is an enzyme involved in the glycosylation of proteins, specifically alpha-dystroglycan, by catalyzing the transfer of ribitol-phosphate groups in the Golgi apparatus[1][2][5]. This glycosylation is essential for alpha-dystroglycan to anchor the cell’s cytoskeleton to the extracellular matrix, which is critical for the stability and integrity of skeletal and cardiac muscle fibers, as well as for aspects of brain and eye development[1][2][3][5]. Mutations in the FKTN gene cause several forms of congenital muscular dystrophy, notably Fukuyama congenital muscular dystrophy, Walker-Warburg syndrome, limb-girdle muscular dystrophy type 2M, and familial dilated cardiomyopathy due to disruption in alpha-dystroglycan function[1][2][3]. The protein is classified as a ribitol-5-phosphate transferase (an enzyme) and is considered a therapeutic target primarily in the context of gene and molecular therapy for muscular dystrophies[1][3][5]. There are currently no known small-molecule drugs or biologics in clinical use which directly target fukutin, but its pathway is a focus for gene therapy research. Mutations or loss of function are severe and often result in multisystem developmental disorders, especially affecting muscles, brain, and eye[1][2][3].

Other names

Fukuyama-type congenital muscular dystrophy proteinRibitol-5-phosphate transferaseFCMDLGMD2MWalker-Warburg syndrome proteinCMD1XLGMDR13MDDGA4MDDGB4MDDGC4